Magic Genomix is a precision oncology deeptech startup leveraging genomic instability biomarkers to persoanlize cancer treatment and de-risk drug development. Our proprietary platform, including tools like Magic X and Magic Tween, transforms complex clinical and multimodal data into clear, actionable insights.

Magic X analyzes tumor biopsy data to stratify chemotherapy response into three clinically actionable categories: predicted responders, non-responders, and patients at risk of therapy-induced harm. Magic X has demonstrated strong predictive power for chemotherapy response in retrospective soft tissue sarcoma data and is now expanding into ovarian, lung, and breast cancers with targeted and immunotherapy combinations.

With a well-defined path to regulatory approval and commercialization, Magic Genomix is committed to transforming cancer care and improving patient outcomes, one step at a time.

Magic Genomix

Org chart

Teams

Offices